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G-N-3
THINK ABOUT CRYPTOCOCCAL MENINGITIS
K H Chan. K L Tsang, W Mak, RTF Cheung, S L Ho Division of Neurology, University Department of
Medicine, Queen Mary Hospital
Cryptococcus neoformans is regarded as an opportunistic infectious agent for human beings and untreated
cryptococcal meningitis has a very high mortality rate. However, occasional cases of cryptococcal meningitis
occur in apparently normal individuals. This study aims to identify cellular and humoral immunity defects in
cryptococcal meningitis. From May 1996 to June 1999, all patients with CSF culture confirmed cryptococcal
meningitis are studied. Peripheral lymphocyte count, HIV antibody titre, serum immunoglobulin levels are
measured; lymphocyte subset profile by flow cytometry and lymphocyte function test are performed for those
with no obvious causes of immunocompromise found. A total of 6 patients are identified and two had
lymphopenia with positive HIV antibody tests; one patient had dermatomyositis and lymphopenia while taking
oral prednisolone and cyclophosphamide. For the three patients with no obvious cause found, one had reduced
CD4+ T helper cells on lymphocyte subset profile and diagnosed as idiopathic CD4 lymphopenia; the other
two had normal lymphocyte subset profiles but impaired lymphocyte function tests in terms of proliferative
response to phytohaemagglutinin and pokeweed mitogen. All six patients have normal serum immunoglobulin
levels. In conclusion, it seems that all patients with cryptococcal meningitis are immunocompromised in some
ways though the exact underlying causes need further investigations, this is important as immunocompromised
patients with cryptococcal meningitis require long term prophylactic antifungal agents until immunocompetence
is restored
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IN VIVO NEUROPROTECTION OF MELATONIN AGAINST FOCAL CEREBRAL ISCHAEMIA
IN THE RAT
Z. Pei. H.T.S. Ho, S.F. Pang*, and R.T.F. Cheung, Departments of Medicine and Physiology*, Faculty of
Medicine, The University of Hong Kong, Hong Kong
Background and Purpose: Melatonin, the neurohormone secreted predominantly by the pineal gland, plays a
key role in the synchronisation of diurnal rhythms in mammals. Melatonin protects against experimental brain
injury and global cerebral ischaemia. Deficiency of Melatonin after pinealectomy was found to increase the
infarction volume of middle cerebral artery occlusion (MCAO) in rats. In this study, the neuroprotective
effects of exogenous Melatonin were tested in a MCAO stroke model.
Methods: Adult male Sprague-Dawley rats were anaesthetised with sodium pentobarbital to undergo 3-hour
or permanent endovascular right-sided MCAO. Melatonin (1.5, 5, 15, or 50 mg/kg) or the vehicle was given as
a single intraperitoneal (IP) injection at 0.5 hour before the 3-hour MCAO. Another group of rats received an
IP injection of Melatonin (5 mg/kg) at 0.5 hour before permanent MCAO. Body temperature was maintained
constant, and haemodynamic parameters were continuously monitored during the anaesthesia. The rats were
decapitated on day 3, and their brains were cut into 2mm coronal slices before being stained with 2%
triphenyltetrazolium chloride for determination of infarction volume.
Results: After MCAO for 3 hours, the relative infarction volumes were 32.1± 3.9% (mean ± SEM; 11 rats) in
the vehicle-treated group and 27.7±3.8% (10 rats), 17.3+3.4% (9 rats), 24.6±4.5% (9 rats), or 27.7±3.2%
(9 rats) in the groups treated with Melatonin at 1.5, 5, 15, or 50 mg/kg, respectively. The relative infarct
volume was 17.0± 6.5% (8 rats) after the permanent MCAO and an IP dose of Melatonin at 5 mg/kg. In both
3-hour and permanent MCAO, the reduction in infarction volume was statistically significantly with an IP
dose of Melatonin at 5 mg/kg (P < 0.05, 2-tailed student's t test). There was no significant difference in the
haemodynamic parameters among all the groups.
Conclusions: Exogenous Melatonin at 5 mg/kg protects against both transient (3 hours) and permanent focal
cerebral ischaemia in the rat, when given as a single IP dose at 0.5 hour before the MCAO. Both the non-
receptor mediated (such as antioxidant effects) and receptor-mediated actions of Melatonin may influence the
infarction volume of focal cerebral ischaemia. Melatonin at the present doses does not produce any significant
haemodynamic effect.
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